AVEO Oncology, an LG Chem company
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. AVEO’s strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to do the same in other geographies. In March 2021, AVEO received FDA approval of FOTIVDA® (tivozanib). To learn more about FOTIVDA efficacy, safety, and relevant resources, visit our website at FOTIVDAHCP.com or click the link below.
Brands: https://events.jspargo.com/ASCO21/CUSTOM/AVEO%20Banner.png
Press Releases
Products